Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

RecruitingOBSERVATIONAL
Enrollment

1,020

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

May 1, 2028

Conditions
Pancreas AdenocarcinomaSmall-cell Lung CancerGlioblastoma, IDH-wildtype
Interventions
GENETIC

Long term survival multimodal analysis

"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"

Trial Locations (1)

94805

RECRUITING

Gustave Roussy Cancer Campus, Grand Paris, Villejuif

All Listed Sponsors
collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

collaborator

Centre Leon Berard

OTHER

collaborator

Vall d'Hebron Institute of Oncology

OTHER

collaborator

Istituto Europeo di Oncologia

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

lead

Cure 51

OTHER